dual gip and glp-1 receptor agonist Tirzepatide's Unique Mechanism of Action Oral GLP-1-Based Therapeutics in the
Description
Pharmacokinetics and safety of Iglarlixi in healthy chinese participants: Results of a phase 1 randomized study

Therefore, during DUL treatment, we should pay close attention to the related signs of pancreatitis, and if pancreatitis occurs, we need to stop the drug immediately (113)

This change was accompanied by a decrease in thyroid calcitonin expression
More comprehensive insight into the effects of GLP-1 RAs on gastrointestinal and central nervous system functions is required

Diabetes (2014) 63:334658

48 , e219 (2016)
